3M (MMM) Q2 2024 earnings summary

Executive summary

• Reported Q2 adjusted EPS of $1.93, up 39% year-over-year, with adjusted sales of $6.0B and strong operational execution, especially in electronics, despite mixed industrial and soft consumer demand.

• Completed the spin-off of the Health Care business (Solventum), now an independent public company, with ongoing transition services and commercial agreements.

• Transformation efforts include restructuring, portfolio shifts, PFAS exit by end of 2025, and major legal settlements.

• CEO priorities: drive sustained organic growth, improve operational performance, reinvigorate R&D, and deploy capital effectively.

• Focus on disciplined capital allocation, operational excellence, and addressing aging product portfolio.

Financial highlights

• Q2 2024 adjusted sales were $6.0B (up 1.2% organically), GAAP sales $6.26B (down 0.5% year-over-year); adjusted operating margin was 21.6% (up 440 bps), and GAAP operating margin 20.3%.

• Adjusted EPS was $1.93, up 39% year-over-year; GAAP EPS from continuing operations was $2.17.

• Adjusted free cash flow was $1.2B, with a 109% conversion rate; operating cash flow was $1.0B.

• Net income from continuing operations was $1.2B, compared to a loss of $7.2B in Q2 2023.

• $0.8B returned to shareholders via dividends and share repurchases in Q2.

Outlook and guidance

• Raised full-year 2024 adjusted EPS guidance to $7.00–$7.30, up 16%–21% year-over-year.

• Full-year adjusted operating margin expected to rise 225–275 bps; organic sales growth guidance flat to up 2%.

• Adjusted total sales growth forecasted at (0.25%) to +1.75% for 2024.

• Second half organic growth expected to be in line with first half at midpoint.

• Pre-tax restructuring charges for the year expected at $250–$300 million.